Evotec and APEIRON Biologics build Pain Alliance

Wednesday, 27. October 2010 07:26
Evotec AG /
Evotec and APEIRON Biologics build Pain Alliance
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.

Hamburg, Germany - 27 October 2010: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) today announced that it has entered into a collaboration with Apeiron
Biologics AG, to initially identify small molecule modulators of DREAM
(Downstream Regulatory Element Antagonistic Modulator), a novel target involved
in perception of various pain mechanisms. Further projects will be evaluated to
potentially expand this cooperation in due course.

Evotec will apply, in a first instance, its expertise in cellular assay
development with opportunities for the project to rapidly move into hit
identification and beyond.

Dr Hans Loibner, Chief Executive Officer at Apeiron Biologics, commented:
"Combining our two companies' skills is an excellent way to move forward with
this innovative and promising project. We have worked with Evotec in the past
and continue to be impressed by the quality of the work performed there."

Dr Werner Lanthaler, Chief Executive Officer at Evotec stated: "Apeiron is
certainly one of the most exciting young biotech companies in Europe. We are
happy that through the optimal use of R&D outsourcing Evotec can add value
here."

No financial details are disclosed.

ABOUT DREAM
Downstream Regulatory Element Antagonistic Modulator (DREAM) is a key molecule
for pain regulation: By binding on the respective DNA-promoter region, DREAM
inhibits the synthesis of the endogenous opioid precursor prodynorphin and
therefore may represent a new target for the treatment of pain. As shown by
DREAM knock-out mice, loss of DREAM broadly reduces pain, ranging from acute
chemical, heat, or mechanical to internal, inflammatory, and chronic neuropathic
pain.
Substances that release DREAM from the respective DNA and thereby activate the
synthesis of the endogenous opioid precursor prodynorphin in essence are not
analgesics per se, but trigger the production of endogenous opioids in the
treated individual. Following high throughput screening and hit optimization, a
first set of compounds already has been identified that selectively release
bound DREAM from the respective DNA motif.

Contact: Dr Werner Lanthaler, Chief Executive Officer,
Evotec AG, Tel.: +49.(0)40.56081-242, werner.lanthaler@evotec.com

Forward-Looking Statements - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. Such forward-looking statements include, but are not limited to,
statements about our 2010 financial outlook and our expected financial results
in future quarters, our revised revenue guidance for 2010 and expected revenue
growth, our ability to deliver on our liquidity guidance, our belief that we are
on course to sustainable profitability latest in 2012, our expectations and
assumptions concerning regulatory, clinical and business strategies, the
progress of our clinical development programmes and timing of the commencement
and results of our clinical trials, strategic collaborations and management's
plans, objectives and strategies. These statements are neither promises nor
guarantees, but are subject to a variety of risks and uncertainties, many of
which are beyond our control, and which could cause actual results to differ
materially from those contemplated in these forward-looking statements. In
particular, the risks and uncertainties include, among other things: risks that
product candidates may fail in the clinic or may not be successfully marketed or
manufactured; the risk that we will not achieve the anticipated benefits of our
collaborations, partnerships and acquisitions in the timeframes expected, or at
all; risks relating to our ability to advance the development of product
candidates currently in the pipeline or in clinical trials; our inability to
further identify, develop and achieve commercial success for new products and
technologies; the risk that competing products may be more successful; our
inability to interest potential partners in our technologies and products; our
inability to achieve commercial success for our products and technologies; our
inability to protect our intellectual property and the cost of enforcing or
defending our intellectual property rights; our failure to comply with
regulations relating to our products and product candidates, including FDA
requirements; the risk that the FDA may interpret the results of our studies
differently than we have; the risk that clinical trials may not result in
marketable products; the risk that we may be unable to successfully secure
regulatory approval of and market our drug candidates; and risks of new,
changing and competitive technologies and regulations in the U.S. and
internationally.

The list of risks above is not exhaustive. Our most recent Annual Report on Form
20-F, filed with the Securities and Exchange Commission, and other documents
filed with, or furnished to the Securities and Exchange Commission, contain
additional factors that could impact our businesses and financial performance.
We expressly disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change in our
expectations or any change in events, conditions or circumstances on which any
such statement is based.



[HUG#1455521]



--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


Pdf of Press Release:
http://hugin.info/131215/R/1455521/395394.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Evotec AG via Thomson Reuters ONE
Related Links: Evotec SE
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.